Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
Holding ALT?
Track your performance easily
ALT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.32 - $14.84
Previous Close$7.68
Volume1.94M
Average Volume (3M)2.13M
Market Cap
$530.19M
Enterprise Value$365.28M
Total Cash (Recent Filing)$164.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 12, 2024EPS Estimate
-$0.36Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding71,070,951
10 Day Avg. Volume2,411,229
30 Day Avg. Volume2,132,296
Standard Deviation0.56
R-Squared0.00004
Alpha0.11
Financial Highlights & Ratios
Price to Book (P/B)3.57
Price to Sales (P/S)1296.31
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue893.11
Enterprise Value/Gross Profit857.47
Enterprise Value/Ebitda-3.72
Forecast
1Y Price Target
$21.20Price Target Upside176.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Altimmune News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsOngoing Ph. II non-cirrhotic MASH study strong execution, translating to 'fastest enrollment' ever seen with any Ph. II liver biopsy study.
Market PositionThe scarcity of similar candidates in biotech companies positions pemvidutide favorably in the market.
Product DevelopmentManagement is continuing development of an oral formulation of pemvi, offering the same weight loss and potency alongside tolerability profile, allowing differentiation from mono GLP1 oral small molecule programs.
Bears Say
Clinical TrialsSurvodutide has superior weight loss and improvement in HbA1c but at the cost of worse tolerability, which is not expected to improve significantly in Phase 3.
Drug DevelopmentSurvodutide data show one of the worst tolerability profiles for a GLP-based candidate.
Product PipelineThe company is discontinuing development of hepatitis B candidate HepTCell which we considered upside, and thus has no impact on our valuation.
---
Ownership Overview
0.83% Insiders
11.78% Mutual Funds
1.45% Other Institutional Investors
71.89% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALT FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $2.31 and its highest was $14.84 in the past 12 months.
What is Altimmune Inc’s market cap?
Currently, no data Available
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Nov 12, 2024 which is in 2 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Aug 08, 2024. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.349 by -$0.001.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Notavailable dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -$0.36.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 71,070,950 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.349. Following the earnings report the stock price went up 15.091%.
Which hedge fund is a major shareholder of Altimmune Inc?
Among the largest hedge funds holding Altimmune Inc’s share is Ardsley Advisory Partners. It holds Altimmune Inc’s shares valued at 2M.
---
Altimmune Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.20 (176.04% Upside)
$21.20 (176.04% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 97%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 681.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $110.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
184.44%
12-Months-Change
Fundamentals
Return on Equity
-63.29%
Trailing 12-Months
Asset Growth
-5.44%
Trailing 12-Months
Company Description
Altimmune Inc
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
ALT Earnings Call
Q2 2024
0:00 / 0:00
---
ALT Stock 12 Month Forecast
Average Price Target
$21.20
▲(176.04% Upside)
Technical Analysis
Best Analysts Covering ALT
1 Year
1 Year Success Rate
18/35 ratings generated profit
1 Year Average Return
+8.26%
reiterated a buy rating last month
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 51.43% of your transactions generating a profit, with an average return of +8.26% per trade.
---